Courtesy of The Joint Blog
A new study published in the journal
Cell Immunology has
found that activation of the body’s cannabinoid receptors - something
done naturally by cannabis and cannabinoids – has neuroinflammatory
capabilities.
According to the study; “Here we showed that Gp1a, a
highly selective CB2 [cannabinoid receptor 2] agonist, with a four log
higher affinity for CB2 than CB1, reduced clinical scores and
facilitated recovery in EAE [experimental autoimmune encephalomyelitis, a
disease of the central nervous system] in conjunction with long term
reduction in demyelination and axonal loss.”
The study continues;
“This is the first report on the in vivo CB2-mediated Gp1a inhibition of
Th17/Th1 differentiation. We also confirmed the Gp1a-induced inhibition
of Th17/Th1 differentiation in vitro, both in non-polarizing and
polarizing conditions. The CB2-induced inhibition of Th17
differentiation is highly relevant in view of recent studies emphasizing
the importance of pathogenic self-reactive Th17 cells in EAE/MS.
Researchers
conclude that “the combined effect on Th17 differentiation and immune
cell accumulation into the CNS, emphasize the relevance of CB2 selective
ligands as potential therapeutic agents in neuroinflammation.”
The
study was conducted by researchers at the Temple University School of Medicine in Philadelphia.
Source:
TheJointBlog.Com
Maryland -- The move to legalize marijuana in
Maryland has a powerful ally: Senate President Thomas V. Mike Miller Jr.
Miller (D-Calvert), who has presided over his chamber for more than a
quarter century, said in an interview Friday that he would support
legislation allowing the regulated sale of marijuana, similar to what is
now taking place in Colorado.
